RxDoctor Payments Data

Reem Sharaiha, MD

Gastroenterology · New York, NYNPI 1376701664

Payments from drug & device makers

$135,042in general payments, 2019–2025

Across 297 payments — averaging $454.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$68K
  • Intuitive Surgical$30K
  • Olympus Corporation Of The Americas$12K
  • Wilson Cook Medical Incorporated$10K
  • Pfizer$7K
  • Olympus America Inc.$2K
  • plus $5K from 20 others
$5,204in research payments, 2019–2025

Across 2 payments — averaging $2602.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cook Research Incorporated$5K

What the payments were for

  • Consulting fees$46,31542%
  • Speaking & faculty fees$33,43031%
  • Grants$5000%
  • Travel & lodging$15,76014%
  • Food & beverage$13,34512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,042 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$123,594
Medicare patients
268
Services billed
743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase20$35,229
CreonLipase/Protease/Amylase11$19,032
Esomeprazole Magnesium21$3,533
Omeprazole71$1,261
Levofloxacin60$995
Pantoprazole Sodium42$628
Famotidine18$459
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl12$166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$178$19,03211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →